{
  "id": 18054237,
  "title": "Bukwang Pharmaceutical Signs Saudi Licensing Deal for Diabetes Neuropathy Drug",
  "url": "https://urgent.news/2026/11/04/bukwang-pharmaceutical-signs-saudi-licensing-deal-for-diabetes",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-04T02:22:51.000Z",
  "source": {
    "name": "Korea IT Times",
    "slug": "korea-it-times",
    "url": "https://www.koreaittimes.com/news/articleView.html?idxno=158814"
  },
  "original_language": "en",
  "account": null,
  "summary": "Bukwang Pharmaceutical has signed an exclusive licensing and supply agreement with Saudi pharmaceutical company NASAQ for its diabetes-related neuropathy treatment, Dexid Tablets. This marks the company's first technology export of a self-developed drug in 21 years and aligns with Saudi Arabia's Vision 2030 strategy to localize pharmaceutical manufacturing. Under the five-year contract, NASAQ will handle local regulatory approval, marketing, and distribution, while Bukwang will support the approval process and supply the finished product. The agreement includes a technology transfer for local manufacturing, with the initial purchase commitment of approximately $2.66 million, or 3.7 billion won, and an estimated supply value of $4.53 million, or 6.3 billion won.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}